Luis Cobiella Hernández

Mr. Luis Cobiella Hernández

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Bernardino ClavoBernardino Clavo
Bernardino Clavo
ECELIZABETH CORDOBA-LANUS
ELIZABETH CORDOBA-LANUS
Gregorio Martínez-SánchezGregorio Martínez-Sánchez
Gregorio Martínez-Sánchez
ÁCÁngeles Cánovas-Molina
Ángeles Cánovas-Molina
MFMario Federico
Mario Federico
Francisco Rodríguez-EsparragónFrancisco Rodríguez-Esparragón
Francisco Rodríguez-Esparragón
Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) has been shown to modulate the gut microbiota and reduce inflammation in preclinical models. This article critically examines the evidence on the role of gut dysbiosis in CIPN, evaluates the microbiota-modulating capacity of rectal ozone therapy (OT), and assesses the biological plausibility of ozone as a microbiota-targeting intervention for CIPN, while explicitly distinguishing between established evidence and hypothetical mechanisms. Evidence synthesis: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or fecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and SIRT1 pathways. Preliminary retrospective data from small case series (n = 7 and n = 15) report sustained symptom improvement in CIPN patients receiving OT. However, no human study has directly linked ozone-induced microbiota changes to clinical outcomes, and the clinical evidence for OT in CIPN remains limited to uncontrolled observations. Conclusions: Convergent preclinical evidence supports a biological rationale for investigating ROI as a microbiota-targeting intervention in CIPN. However, this rationale remains largely hypothetical in the clinical setting. High-quality randomized controlled trials with longitudinal microbiome profiling are urgently needed to establish mechanistic causality and to determine whether the promising preclinical findings translate into clinically meaningful benefits. Until such evidence is available, the framework presented here should be regarded as hypothesis-generating rather than as a basis for clinical practice.

29 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Bernardino ClavoBernardino Clavo
Bernardino Clavo
ECELIZABETH CORDOBA-LANUS
ELIZABETH CORDOBA-LANUS
Gregorio Martínez-SánchezGregorio Martínez-Sánchez
Gregorio Martínez-Sánchez
ÁCÁngeles Cánovas-Molina
Ángeles Cánovas-Molina
MFMario Federico
Mario Federico
Francisco Rodríguez-EsparragónFrancisco Rodríguez-Esparragón
Francisco Rodríguez-Esparragón
Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) can modulate the gut microbiota and reduce inflammation. This narrative re-view aims to synthesise evidence on the role of gut dysbiosis in CIPN, evaluate the microbiota-modulating capacity of rectal ozone therapy (OT), and examine the biological plausibility of ozone as a microbiota-targeting intervention for CIPN. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and grey literature for studies published through March 2026 using terms related to CIPN, gut microbiota, dysbiosis, the gut–nerve axis, and OT. Preclinical studies, clinical reports, and systematic reviews were included and narratively synthesised according to the three objectives. Results: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or faecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and sirtuin 1 (SIRT1) pathways. Preliminary retrospective data report sustained symptom improvement in CIPN patients receiving OT, though no study has directly linked ozone-induced microbiota changes to clinical outcomes. Conclusions: Convergent evidence supports a strong biological rationale for investi-gating ROI as a microbiota-targeting intervention in CIPN. However, high-quality randomised controlled trials with longitudinal microbiome profiling are needed to establish mechanistic causality and guide future supportive care strategies in oncology.